Eduovisual
Human Development
Precocious puberty: workup
— Thelarche, pubarche, testicular enlargement (≥4 mL or ≥2.5 cm length), menarche, voice change, accelerated linear growth
— Tanner staging is the anchor; document at every visit when concerned
— Central (GnRH-dependent, "true") precocious puberty: Premature activation of hypothalamic-pituitary-gonadal (HPG) axis; pubertal progression is isosexual and follows normal sequence
— Peripheral (GnRH-independent, "pseudo") precocious puberty: Sex steroids from gonads, adrenals, exogenous source, or tumor; sequence often disordered (e.g., menses before breast development, virilization in a girl)
— Central PP is ~10× more common in girls and usually idiopathic in girls
— Central PP in boys is pathologic until proven otherwise — CNS lesion in up to 40-75%
— Obesity is a major contributor to earlier thelarche in girls; ethnic variation exists (Black and Hispanic girls earlier on average)
— Tanner 2 breast development before age 8 in a girl, or testicular volume ≥4 mL before age 9 in a boy
— Rapidly progressive puberty (advancing >1 Tanner stage in 3-6 months)
— Growth velocity acceleration, advanced bone age, behavioral changes
— Any virilization in a girl (clitoromegaly, severe acne, hirsutism) or feminization in a boy (gynecomastia with no testicular enlargement) → think peripheral cause
— Premature thelarche (isolated breast budding, often <2 yo, non-progressive)
— Premature adrenarche (isolated pubic/axillary hair, body odor, normal growth velocity)
— Premature menarche (isolated vaginal bleeding without other signs)
Board pearl: In boys, precocious puberty is never assumed idiopathic — MRI brain is mandatory once central PP is confirmed because of high yield for hypothalamic/optic pathway tumors.
— Girls: breast development, pubic hair, unexpected vaginal bleeding, body odor, mood swings, rapid shoe/clothes size changes
— Boys: testicular/penile enlargement, pubic hair, acne, voice deepening, aggressive behavior, erections
— Either: growth spurt noted by parents or school nurse; height crossing percentiles upward
— Slowly progressive over >6 months with normal sequence → likely central
— Rapidly progressive or out-of-order (menarche before thelarche, virilization before testicular growth) → peripheral
— Asymmetric testicular enlargement suggests Leydig cell tumor; symmetric small testes with virilization suggests adrenal source (CAH, adrenal tumor)
— CNS symptoms: headaches, vision changes, seizures, polyuria/polydipsia (diabetes insipidus from hypothalamic lesion), behavioral change
— Skin findings: café-au-lait macules (NF1, McCune-Albright), axillary freckling
— Bone history: fractures with minimal trauma → fibrous dysplasia in McCune-Albright
— Thyroid symptoms (Van Wyk-Grumbach: severe primary hypothyroidism → PP)
— Abdominal pain or mass (ovarian/adrenal tumor)
— Topical testosterone gel on a parent, estrogen creams, OCPs, "natural" supplements, lavender/tea tree oil (gynecomastia), endocrine disruptors
— Always ask: "Does anyone in the household use hormone creams, patches, or gels?"
— Age of puberty/menarche in parents and siblings (familial early puberty)
— CAH, MEN, NF1, McCune-Albright features (precocious puberty + café-au-lait + fibrous dysplasia)
— Consanguinity → consider familial male-limited PP (testotoxicosis), autosomal dominant LH receptor activation
— Plot all available heights and weights; upward crossing of percentiles with weight tracking is classic
— Compare to mid-parental height
Step 3 management: A 7-year-old girl with Tanner 3 breasts that appeared 4 months ago and a 4 cm/year growth acceleration → order bone age and basal LH first, do not reassure as "normal variant."
— Height, weight, BMI plotted; compute growth velocity (cm/year) from prior visits
— Mid-parental height: girls = (paternal − 13 + maternal)/2; boys = (paternal + maternal + 13)/2
— Sitting height/leg length ratio if disproportion suspected
— Breast stages B1-B5 by inspection AND palpation (distinguish lipomastia from true glandular tissue — palpate for breast bud disc beneath areola)
— Pubic hair stages PH1-PH5 in both sexes; axillary hair separately
— Genital staging in boys: Orchidometer measurement of testicular volume is the single most important exam finding
— ≥4 mL = pubertal activation (central PP if bilateral)
— Prepubertal testes with virilization → adrenal or exogenous source
— Asymmetric testes → tumor (Leydig, gonadoblastoma)
— Café-au-lait macules: smooth "coast of California" borders → McCune-Albright; jagged "coast of Maine" + axillary freckling → NF1
— Acne distribution, oily skin, hirsutism (Ferriman-Gallwey if applicable)
— Acanthosis nigricans (insulin resistance, obesity-related)
— Visual fields (bitemporal hemianopsia → suprasellar lesion)
— Cranial nerves, fundoscopy for papilledema
— Gait, coordination
— Palpate for adrenal or ovarian mass
— External genital exam in girls: clitoral size (clitoromegaly >1 cm → androgen excess), estrogenization of vaginal mucosa (pink, moist, dulled vs. red, thin = prepubertal)
— In boys: penile length and stretched penile length, hyperpigmentation of scrotum (androgen exposure), testicular asymmetry
Key distinction: Bilateral testicular enlargement ≥4 mL = central PP. Prepubertal testes (<4 mL) with virilization = peripheral PP (adrenal, exogenous androgen, or — rarely — hCG-secreting tumor with symmetric but only mild testicular enlargement). This single finding directs your entire workup.
— Order in every suspected case
— Bone age advanced ≥2 SD beyond chronologic age supports true pubertal exposure
— Bone age = chronologic age → likely benign variant (premature thelarche/adrenarche)
— Used to predict adult height (Bayley-Pinneau tables) and guide treatment decisions
— LH (ultrasensitive/3rd-generation assay) is the cornerstone
— Basal LH ≥0.3 IU/L (some labs ≥0.2) suggests central PP
— Suppressed LH with elevated estradiol/testosterone → peripheral PP
— FSH
— Estradiol (girls): >20 pg/mL suggests ovarian estrogen production; very high (>100) → consider ovarian cyst/tumor or McCune-Albright
— Total testosterone (boys): pubertal levels confirm activation
— TSH, free T4 — rule out Van Wyk-Grumbach (severe primary hypothyroidism with PP and delayed bone age — the exception to the "advanced bone age" rule)
— DHEAS (adrenal marker; mildly elevated in premature adrenarche, markedly elevated in adrenal tumor)
— 17-hydroxyprogesterone (screen for non-classic CAH; >200 ng/dL basal warrants ACTH stim test)
— Androstenedione, total/free testosterone
— Consider cortisol if Cushing features
— β-hCG-secreting germ cell tumors (pineal, hepatic, mediastinal) cause isolated Leydig cell stimulation → testosterone rise with only mildly enlarged testes
CCS pearl: Order bone age + LH + FSH + estradiol (girls) or testosterone (boys) + TSH simultaneously on the first visit. Don't sequentially trickle labs — Step 3 rewards efficient parallel workup that produces actionable answers within one clinic cycle.
— Indication: clinical suspicion of central PP with non-diagnostic basal LH (<0.3 IU/L) but progressive puberty
— Administer leuprolide (or native GnRH where available); measure LH at 30-60 min
— Stimulated LH peak ≥5 IU/L (varies by assay, often ≥4-5) confirms central activation
— LH/FSH ratio >1 favors central; FSH-predominant response suggests prepubertal pattern
— Uterine length >3.5 cm, endometrial stripe presence, ovarian volume >2-3 mL, follicles >9 mm support estrogen exposure
— Identifies ovarian cysts (McCune-Albright, autonomous follicular cyst) or ovarian/adrenal masses in peripheral PP
— Mandatory in confirmed central PP if:
— Any boy with central PP
— Girls <6 years old
— Any patient with neurologic symptoms, rapid progression, or atypical features
— Optional/individualized in girls 6-8 years with otherwise classic idiopathic-appearing central PP (recent guidelines allow shared decision-making, but many experts still image)
— Yield: hypothalamic hamartoma (classic — non-progressive, may also cause gelastic seizures), optic glioma, craniopharyngioma, germinoma, arachnoid cyst, hydrocephalus, prior CNS radiation/trauma
— CT or MRI adrenals if adrenal androgens markedly elevated or virilization with prepubertal LH/testes
— ACTH stimulation test if 17-OHP elevated → non-classic CAH
— Aromatase activity, DHT in unusual disorders of sex development
— Genetic testing: GNAS mosaicism (McCune-Albright — blood often negative, may need affected tissue), LHCGR (testotoxicosis), MKRN3 and DLK1 (familial central PP)
Board pearl: Hypothalamic hamartoma is the most common CNS lesion causing central PP — congenital, non-neoplastic, treat the PP medically (GnRH agonist), surgery only for refractory seizures.
— Central PP confirmed (pubertal LH, advanced bone age, progressive Tanner):
— Image brain → treat underlying lesion if found + GnRH agonist
— Idiopathic → GnRH agonist if criteria met
— Peripheral PP:
— Identify and treat source (exogenous exposure removal, tumor resection, CAH glucocorticoids, McCune-Albright aromatase inhibitor or selective ER modulator)
— Watch for secondary central activation once peripheral source removed and bone age advanced — may then require GnRH agonist
— Goals: Preserve adult height potential, halt/regress secondary sexual characteristics, reduce psychosocial distress
— Best candidates:
— Onset <6 years (largest height benefit)
— Rapidly progressive puberty
— Bone age significantly advanced with predicted adult height below mid-parental target or <150 cm girls / <160 cm boys
— Significant psychosocial impact
— May not benefit:
— Slowly progressive PP with preserved height potential — observation appropriate
— Onset close to age 8 (girls) / 9 (boys) with predicted height in target range
— Premature thelarche or adrenarche alone — observe
— Every 3-6 months: Tanner staging, growth velocity, bone age every 6-12 months
— Re-stratify if rapid progression appears
— Pediatric endocrinology drives management
— Neurosurgery/oncology if CNS or peripheral tumor
— Psychology/social work for behavioral/emotional support — early puberty correlates with depression, anxiety, earlier sexual debut, risk-taking
Step 3 management: Don't reflexively treat every child with PP. Document trajectory over 3-6 months with serial exams and bone age before committing to GnRH agonist therapy unless tempo is clearly rapid or onset is very young.
— Continuous (non-pulsatile) GnRH receptor stimulation → pituitary desensitization → suppressed LH/FSH → suppressed gonadal sex steroid output
— Initial flare (1-2 weeks of stimulation) can transiently worsen symptoms; in girls may cause withdrawal bleed when therapy starts
— Leuprolide depot IM: 7.5-15 mg every 4 weeks, or 11.25-30 mg every 12 weeks (3-month depot most commonly used)
— Leuprolide 6-month depot (45 mg SC): improved adherence
— Triptorelin depot: 22.5 mg every 24 weeks
— Histrelin SC implant: lasts 12 months (some data up to 2 years), placed in upper arm under local anesthesia — excellent for adherence challenges
— Nasal/daily preparations rarely used in PP
— Measure LH (basal and/or stimulated post-leuprolide injection) and estradiol/testosterone 3-6 months after initiation
— Goals: LH <4 IU/L stimulated, prepubertal sex steroid levels, halted/regressed Tanner progression, decelerated bone age advancement
— Growth velocity should normalize or slow; predicted adult height should improve
— Local injection site reactions (sterile abscess in 5-10%)
— Headache, hot flashes (uncommon in children)
— Mood changes
— Bone mineral density: transiently decreased during therapy, recovers after discontinuation — counsel on calcium/vitamin D, weight-bearing activity
— Rare: pseudotumor cerebri, anaphylaxis
— Girls: typically around bone age 12-12.5 years or chronologic age 11
— Boys: bone age 13-13.5 years or chronologic age 12
— Stopping triggers resumption of puberty within 6-18 months; menarche typically 1-2 years after stopping in girls
Board pearl: The leuprolide-stimulated LH level (drawn 30-60 min after injection) is the standard for both diagnosis and monitoring response to GnRH agonist therapy.
— Letrozole (aromatase inhibitor) — first-line; blocks peripheral estrogen synthesis
— Tamoxifen (SERM) alternative
— Fulvestrant (selective estrogen receptor degrader) — newer option
— GnRH agonist added only if secondary central PP develops
— Bisphosphonates for fibrous dysplasia pain/fractures; treat endocrinopathies (hyperthyroidism, GH excess, Cushing)
— Combination therapy: ketoconazole (steroidogenesis inhibitor; monitor LFTs, adrenal axis) or spironolactone + an aromatase inhibitor (anastrozole/letrozole) to block androgen action and conversion to estrogen
— Add GnRH agonist when secondary central PP develops
— Hydrocortisone 10-15 mg/m²/day divided TID (in children) to suppress ACTH and adrenal androgens
— Monitor 17-OHP, androstenedione, growth velocity, bone age
— Mineralocorticoid (fludrocortisone) if salt-wasting variant
— Stress-dose steroids for illness/surgery — must teach family
— Surgical resection is definitive
— Pre-op imaging staging; post-op surveillance for recurrence
— Adrenocortical carcinoma → mitotane consideration with oncology
— Localize (brain, mediastinum, liver, gonad), resect, chemotherapy per oncology
— Tumor markers (β-hCG, AFP) trend post-treatment
— Remove the source — counsel parents on testosterone gel hygiene (wash hands, cover application sites, no skin-to-skin transfer)
— Symptoms typically regress within months; bone age may remain advanced
— Levothyroxine replacement — PP resolves; bone age (initially delayed, unusual feature) normalizes
Key distinction: Peripheral PP that advances bone age sufficiently can prime the hypothalamus and trigger secondary central PP. After treating the peripheral source, monitor LH — if it rises, add a GnRH agonist.
— Precocious puberty is by definition pediatric; "elderly" and adult organ-impairment dosing aren't directly relevant
— Step 3 focus shifts to comorbid conditions in children that alter workup or therapy
— Often associated with delayed, not precocious, puberty
— GnRH agonist clearance not significantly altered; standard dosing
— Monitor for cumulative growth impact — CKD already compromises height
— Ketoconazole (used for testotoxicosis) is hepatotoxic — monitor AST/ALT every 2-4 weeks initially, then every 3 months; avoid in pre-existing liver disease
— Aromatase inhibitors metabolized hepatically — caution and dose adjustment in significant impairment
— Strongly associated with earlier thelarche and pubarche in girls
— Often presents as borderline early puberty with normal trajectory
— Address weight management; avoid over-medicalizing isolated early thelarche in an obese girl with bone age within 1 SD
— History of CNS radiation (e.g., for ALL, medulloblastoma) is a major risk factor for central PP — these survivors need pubertal monitoring from age 6
— Cerebral palsy, hydrocephalus, prior meningitis also raise risk
— Late effects clinics should screen routinely
— Children adopted internationally, particularly from low-resource settings, have higher rates of central PP — proposed mechanism: catch-up nutrition and growth
— Screen at intake and at 6-12 month follow-up
— NF1: screen with optic pathway MRI; optic glioma can cause central PP
— Williams syndrome: modestly increased PP risk
— Russell-Silver, prior IUGR: earlier adrenarche/puberty
— Down syndrome: typically normal or slightly delayed; evaluate any early signs
Step 3 management: A cancer survivor who received cranial radiation presenting with Tanner 2 breast at age 7 needs the full PP workup — radiation-induced central PP is common and the bone age may already be significantly advanced at first evaluation.
— Termed "early but normal" puberty rather than precocious
— Workup individualized by tempo, predicted height, psychosocial impact
— Often observation alone; GnRH agonist controversial — reserve for rapid progression with compromised height prediction
— Most common in infants 6-24 months — transient mini-puberty
— No pubic hair, no growth acceleration, normal bone age, normal estradiol
— Observe with reassurance; resolves spontaneously
— Re-evaluate if pubic hair, growth velocity acceleration, or progression beyond Tanner 3 develops
— Pubic/axillary hair, body odor, mild acne in girls <8 / boys <9 without thelarche or testicular enlargement
— DHEAS mildly elevated, normal LH/estradiol/testosterone, bone age within 2 SD
— Long-term association with PCOS, metabolic syndrome, insulin resistance — counsel on lifestyle, monitor BMI
— Rule out non-classic CAH if bone age advanced or virilization
— Ambiguous genitalia at any age requires urgent multidisciplinary evaluation — pediatric endocrine, urology, genetics, psychology, ethics
— Karyotype, AMH, testosterone/DHT ratio, electrolytes (CAH), pelvic imaging
— Avoid gender assignment until full evaluation; involve family in informed, ethically guided decisions
— Explain the distinction between physical maturity and emotional/cognitive age — a Tanner 3 7-year-old is still 7 cognitively
— Discuss bullying risk, body image, age-inappropriate attention from peers and adults
— Anticipatory guidance on safety, hygiene (menarche), and abuse prevention
— Address parental anxiety about adult height and fertility (fertility is preserved with appropriate treatment)
CCS pearl: Always involve a pediatric psychologist or social worker for any child being treated for PP — psychosocial outcomes are part of the standard of care and are an expected Step 3 management element.
— Short adult stature: Premature epiphyseal fusion from accelerated bone age — final height often 150 cm in girls, 155-160 cm in boys without treatment when onset is very early
— Loss of 5-20 cm of adult height potential possible with onset <6 years
— Increased risk of:
— Depression, anxiety, low self-esteem
— Earlier sexual debut, increased risk-taking, substance use
— Body image disturbance, eating disorders
— Peer rejection, bullying, sexual harassment
— Girls with early menarche have higher lifetime risk of mood disorders
— Earlier menarche → increased lifetime estrogen exposure → modestly increased risk of breast cancer and endometrial cancer in adulthood
— Association with PCOS, metabolic syndrome, type 2 diabetes, particularly when PP follows premature adrenarche pattern
— Cardiovascular disease risk modestly elevated
— CNS tumor progression if MRI not obtained — visual loss, hydrocephalus, hypothalamic dysfunction (DI, panhypopituitarism), gelastic seizures (hamartoma)
— Adrenal or gonadal malignancy progression if peripheral PP not investigated
— Adrenal crisis if undiagnosed CAH stressed (illness, surgery)
— Sterile abscesses at injection site
— Transient bone density reduction (typically recovers)
— Anaphylaxis (rare)
— Pseudotumor cerebri — rare; consider in patient with persistent headaches and papilledema
— Slipped capital femoral epiphysis (rare association with rapid hormonal shifts)
— Pituitary/hypothalamic surgery → panhypopituitarism, diabetes insipidus, hypothalamic obesity
— Adrenalectomy → lifelong replacement if bilateral
Board pearl: The two most consequential complications of unrecognized PP are short adult stature and missed CNS tumor in boys — both are why workup must be thorough and timely.
— Any confirmed Tanner 2+ before age 8 (girls) / 9 (boys)
— Rapidly progressive puberty
— Asymmetric testicular enlargement, virilization in a girl, or feminization in a boy
— Family history of testotoxicosis, CAH, McCune-Albright
— Boys with central PP — MRI brain ASAP
— Neurologic signs: headache, vision change, vomiting, polyuria/polydipsia, behavior change, gelastic seizures
— Severe virilization suggesting adrenal carcinoma
— Markedly elevated DHEAS, testosterone, or estradiol on initial screen
— Palpable abdominal or pelvic mass
— Newly identified CNS tumor with mass effect, hydrocephalus, or visual compromise → neurosurgery
— Adrenal crisis in newly diagnosed CAH — IV hydrocortisone, fluids, electrolyte correction
— Severe hypothyroidism with myxedema features (Van Wyk-Grumbach extreme cases)
— Suspected sexual abuse revealed during exam → child protective services + safe placement; admission if disposition uncertain
— Pediatric endocrinology (primary)
— Pediatric neurosurgery / neuro-oncology (CNS lesion)
— Pediatric urology / surgical oncology (gonadal/adrenal tumor)
— Genetics (suspected syndromic causes)
— Child psychology / psychiatry / social work
— Ophthalmology (visual fields, optic glioma surveillance in NF1)
— Direct communication between PCP and endocrinologist about which labs are pending speeds care
— Provide endocrinologist with bone age film and report, growth charts, and parental heights
Step 3 management: A 6-year-old boy with new Tanner 3, headaches, and a basal LH of 2 IU/L needs same-week brain MRI, not a routine 6-week endocrine appointment — escalate directly.
— Idiopathic (most common in girls 6-8)
— Hypothalamic hamartoma — congenital, may have gelastic (laughing) seizures
— Optic pathway glioma — especially in NF1
— Craniopharyngioma — typically presents with growth failure + visual changes, but can rarely cause central PP early in course
— Germinoma — pineal/suprasellar; β-hCG, AFP markers
— CNS infection sequelae (TB meningitis, abscess), trauma, radiation, hydrocephalus
— Genetic: MKRN3 loss-of-function (paternally inherited), DLK1, KISS1, KISS1R activating mutations
— Ovarian:
— Autonomous follicular cyst (often McCune-Albright)
— Granulosa cell tumor (estrogen-secreting)
— Sertoli-Leydig tumor (rare, virilizing)
— Testicular:
— Leydig cell tumor (asymmetric testicular enlargement, testosterone↑, LH suppressed)
— Familial male-limited PP (testotoxicosis)
— Adrenal:
— Congenital adrenal hyperplasia (non-classic 21-OH most common; also 11β-OH, 3β-HSD)
— Adrenal adenoma or carcinoma (rapid, severe virilization; DHEAS very high)
— hCG-secreting germ cell tumors (boys only — Leydig stimulation): hepatoblastoma, mediastinal, intracranial pineal germinoma
— Exogenous hormone exposure (testosterone gel transfer, estrogen creams, OCP ingestion, anabolic supplements)
— McCune-Albright syndrome (GNAS mosaicism) — café-au-lait, fibrous dysplasia, multiple endocrinopathies
— Severe primary hypothyroidism (Van Wyk-Grumbach) — high TSH cross-reacts with FSH receptor
— Long-standing peripheral PP advances bone age, primes hypothalamus → secondary central activation
Key distinction: LH level is the great divider — pubertal/elevated LH = central; suppressed LH with elevated sex steroids = peripheral. From there, sex steroid pattern (estrogen vs androgen) and imaging localize the lesion.
— Premature thelarche — isolated breast tissue, often <2 yo or 6-8 yo; no other pubertal signs, normal bone age, non-progressive
— Premature adrenarche — isolated pubic/axillary hair, body odor; DHEAS mildly elevated, normal LH/estradiol
— Premature menarche — isolated vaginal bleeding without other Tanner progression; rule out other bleeding causes first
— Vaginal bleeding mimics:
— Foreign body (toilet paper, small objects) — foul-smelling discharge, intermittent bleeding → exam under anesthesia
— Vulvovaginitis (group A strep, Shigella)
— Urethral prolapse (especially Black girls 4-8 yo) — friable doughnut-shaped tissue
— Lichen sclerosus — figure-8 white atrophic skin, bleeding from trauma
— Sexual abuse — always consider; document and report per state law
— Sarcoma botryoides (rare vaginal rhabdomyosarcoma) — grape-like mass
— Breast enlargement mimics:
— Lipomastia in obese children — no palpable glandular disc
— Neonatal gynecomastia — maternal estrogen withdrawal, self-limited
— Drug-induced gynecomastia (spironolactone, ketoconazole, cimetidine)
— Pubic hair mimics:
— Localized vellus hair, hypertrichosis (medication-induced — minoxidil, phenytoin, cyclosporine)
— Hair pulling/manipulation artifact
— Sexual abuse presenting as vaginal bleeding, behavioral changes, or unexplained "puberty" — mandatory consideration
— Constitutional advancement of growth — early but normal-pattern puberty in a tall child with family history of early puberty
— Pseudoprecocious puberty from oral contraceptive pill ingestion by a child (accidental exposure)
Board pearl: Vaginal bleeding in a prepubertal girl without breast development should prompt search for foreign body, trauma, infection, urethral prolopse, or sexual abuse — not an immediate hormonal workup. Examine carefully and consider exam under anesthesia.
— Continue therapy until bone age 12-12.5 (girls) / 13-13.5 (boys) or as individualized for height optimization
— Periodic medication adherence checks; switch to histrelin implant if adherence is poor with injections
— Nutrition: adequate calcium (1300 mg/day age 9-18) and vitamin D (600-1000 IU/day) to support bone mineralization
— Weight-bearing physical activity
— Maintain healthy BMI — obesity worsens metabolic outcomes
— Counsel family well in advance about expected timeline of pubertal resumption
— After stopping: first menses typically within 12-18 months in girls
— Final adult height attained 1-3 years after cessation in girls, longer in boys
— Track predicted vs. actual adult height annually
— Bone density: routine DXA not required unless additional risk factors; bone density recovers post-treatment
— Reproductive function: fertility preserved with appropriate management — reassure family
— Mental health: annual screen for depression, anxiety, body image issues; particularly in adolescence
— Metabolic: lipid panel, fasting glucose, blood pressure during adolescence — especially if premature adrenarche history or PCOS features developing
— Hypothalamic hamartoma: non-progressive — neurology follow-up for seizure control only
— Optic pathway glioma: ophthalmology + neuro-oncology surveillance per protocol
— NF1: lifelong tumor screening
— McCune-Albright: monitor for hyperthyroidism, GH excess, Cushing, fibrous dysplasia complications, café-au-lait surveillance
— CAH: lifelong endocrine follow-up, fertility counseling at appropriate age, stress-dose steroid education
— HPV vaccination at age 9 (now recommended starting age 9; particularly relevant if menarche imminent)
— Routine well-child care, adolescent risk-behavior screening earlier given physical maturity
Step 3 management: Stop GnRH agonist at bone age ~12 in girls — continuing longer offers no further height benefit and prolongs HPG suppression unnecessarily.
— Clinic visit every 3-6 months with Tanner staging, growth velocity, weight
— Bone age every 6-12 months
— Repeat hormonal labs if exam progresses or trajectory uncertain
— Re-image brain only if new neurologic signs (initial MRI sufficient otherwise)
— Visit every 3-6 months
— At each visit: Tanner staging (expect arrest or regression), height/weight, growth velocity, side effect review, injection site check
— Labs every 6 months: basal or leuprolide-stimulated LH, estradiol (girls) or testosterone (boys) to confirm suppression
— Bone age every 6-12 months to confirm deceleration and estimate predicted adult height
— Adherence verification; verify injection schedule completion
— Tanner stage stable or regressed
— Growth velocity normalized (4-6 cm/year prepubertal range)
— Bone age advancement <1 year per chronologic year
— Suppressed gonadotropins and sex steroids
— Predicted adult height improving toward mid-parental range
— Adherence: importance of on-schedule injections; consequences of missed doses (breakthrough puberty)
— Behavior: body image, peer interactions, sexual safety/abuse prevention (developmentally appropriate)
— Lifestyle: nutrition, calcium/vitamin D, physical activity, sleep
— Family dynamics: parental anxiety, sibling adjustment, school accommodations if needed
— Anticipatory guidance for eventual cessation and resumption of normal pubertal development
— By age 18 or end of puberty, transition from pediatric endocrinology to adult endocrinology or PCP
— Provide written transition summary: diagnosis, treatments, imaging, surgeries, final height, fertility status, ongoing screening recommendations
— Address adolescent autonomy, contraception counseling, mental health continuity
CCS pearl: A structured transition summary at age 18 is a Step 3-favored deliverable — boards reward continuity-of-care documentation, especially for chronic pediatric endocrine conditions moving into adult systems.
— Vaginal bleeding, genital trauma, sexually transmitted infections, or pregnancy in a prepubertal child are mandatory reports to child protective services in all US states
— Pubertal-appearing development does not confer adult cognitive or emotional capacity — vigilance for grooming and abuse is essential
— Physicians who fail to report face civil and criminal liability; report based on reasonable suspicion, not proof
— Parental consent required for evaluation and treatment of minors
— Child assent developmentally appropriate from age 7+; involve the child in discussions about injections, side effects, expected changes
— Document both consent and assent
— Long-acting implants (histrelin) — discuss insertion/removal logistics, scarring, replacement timeline
— As patient ages into adolescence, expand confidential portion of visits (sexual history, mental health, substance use)
— State laws vary on minors' rights to confidential reproductive and mental health care — know your jurisdiction
— Highest-risk handoffs: pediatric endocrine → adult care, primary care turnover, school medical records
— Concrete safety item: Failure to communicate stress-dose steroid requirements in CAH patients across providers can cause adrenal crisis — provide patient and family with medical alert bracelet and written wallet card
— Educate parents about exogenous hormone exposure as a cause of peripheral PP — proper testosterone gel hygiene, locked storage of OCPs and hormone creams
— Document medication reconciliation at every visit; identify accidental exposures
— Insurance coverage for GnRH agonists varies; cost can exceed $1000/month — engage social work and pharmacy assistance programs
— Avoid over-pathologizing normal pubertal timing variation in racial/ethnic groups with earlier physiologic average
— GnRH agonist use in gender dysphoria is a separate, ethically distinct indication — institutional and family-centered protocols apply; not interchangeable with PP management
Board pearl: Mandatory CPS report for unexplained vaginal bleeding or pregnancy in a prepubertal child — this is a frequent Step 3 trap embedded in a workup-style stem.
— Precocious puberty: <8 girls, <9 boys
— Testicular volume ≥4 mL = pubertal activation in boys
— Basal LH ≥0.3 IU/L suggests central PP
— Stimulated LH ≥5 IU/L confirms central PP
— McCune-Albright: Café-au-lait (coast of Maine) + polyostotic fibrous dysplasia + precocious puberty + endocrinopathies (hyperthyroidism, GH excess, Cushing)
— NF1: Café-au-lait (coast of California) + axillary freckling + Lisch nodules + neurofibromas + optic glioma → central PP
— Van Wyk-Grumbach: Severe primary hypothyroidism + PP + galactorrhea + delayed (not advanced) bone age — unique exception
— Familial male-limited PP (testotoxicosis): Autosomal dominant, LHCGR activation, isolated boys, LH suppressed, testosterone elevated
— Central PP: LH↑, FSH↑, estradiol/testosterone↑, bone age↑
— Peripheral PP: LH↓, FSH↓, estradiol/testosterone↑, bone age↑
— Premature thelarche: All normal, breast tissue alone
— Premature adrenarche: DHEAS mildly↑, others normal
— Van Wyk-Grumbach: TSH very↑, T4↓, LH/FSH varies, bone age delayed
— Hypothalamic hamartoma — non-enhancing suprasellar mass on MRI, isointense to gray matter
— Optic glioma — fusiform optic nerve enlargement, NF1-associated
— Ovarian cyst (McCune-Albright) — large, recurrent follicular cysts
— Leuprolide depot — central PP
— Histrelin implant — 12-month adherence-friendly option
— Letrozole/anastrozole — McCune-Albright girls
— Ketoconazole or spironolactone + AI — testotoxicosis
— Hydrocortisone — CAH
— Levothyroxine — Van Wyk-Grumbach
— "Coast of Maine" café-au-lait → McCune-Albright
— "Gelastic seizures" → hypothalamic hamartoma
— "Asymmetric testicular enlargement" → Leydig cell tumor
— "Father using testosterone gel" → exogenous androgen exposure
— "Delayed bone age with precocious puberty" → Van Wyk-Grumbach
Key distinction: Bone age is advanced in essentially all causes of PP except Van Wyk-Grumbach (severe primary hypothyroidism) — a frequently tested exception.
— "A 6-year-old girl is brought in for breast development noted 4 months ago. Exam: Tanner 3 breasts, Tanner 2 pubic hair, growth velocity 9 cm/year. Bone age 9 years. Basal LH 1.2 IU/L, estradiol 35 pg/mL."
— Diagnosis: Central precocious puberty
— Next step: Brain MRI (she is <6-8 with classic features; many programs still image) → then leuprolide depot
— "An 8-year-old boy has pubic hair, facial acne, voice deepening for 6 months. Exam: bilateral testes 6 mL each, Tanner 3 pubic hair, height >97th percentile."
— Diagnosis: Central PP in a boy = always investigate
— Next step: Confirm with LH, then brain MRI is mandatory
— "A 7-year-old boy with pubic hair and acne. Right testis 3 mL, left testis 8 mL. Testosterone elevated, LH suppressed."
— Diagnosis: Leydig cell tumor of left testis
— Next step: Scrotal ultrasound, surgical referral
— "5-year-old girl with irregular vaginal bleeding, large café-au-lait macules with jagged borders, and a recent femur fracture."
— Diagnosis: McCune-Albright syndrome
— Next step: Pelvic US (autonomous cyst), bone survey, letrozole, monitor for other endocrinopathies
— "4-year-old boy with penile enlargement, pubic hair, father uses testosterone gel daily. Prepubertal testes (2 mL bilateral), testosterone elevated, LH suppressed."
— Diagnosis: Peripheral PP from exogenous androgen exposure
— Next step: Remove the source, counsel on hygiene; monitor for regression and secondary central PP
— "8-year-old girl with breast development, weight gain, fatigue, bradycardia, dry skin, growth velocity 2 cm/year, bone age 6 years. TSH 180."
— Diagnosis: Van Wyk-Grumbach (severe hypothyroidism)
— Next step: Levothyroxine — PP regresses
— "5-year-old with vaginal bleeding, no breast or pubic hair development, foul-smelling discharge."
— Diagnosis: Vaginal foreign body (or consider abuse)
— Next step: Exam (possibly under anesthesia), not hormonal workup
Board pearl: When the stem gives you both Tanner stage AND testicular volume in a boy, the testicular volume is the key — symmetric ≥4 mL = central, prepubertal with virilization = peripheral.
Precocious puberty is the appearance of secondary sexual characteristics before age 8 in girls or 9 in boys, requiring workup with Tanner staging, bone age, and basal LH/FSH/sex steroids to distinguish central (GnRH-dependent, treated with GnRH agonists after mandatory brain MRI in all boys and selected girls) from peripheral (GnRH-independent, treated by removing or addressing the underlying gonadal, adrenal, exogenous, or hCG source).
Board pearl: Master the LH-driven decision tree — pubertal LH directs you to MRI and GnRH agonists; suppressed LH with elevated sex steroids directs you to imaging the source and treating peripherally.